BOULDER, Colo., May 5 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase I study of N30-201 in patients with mild to moderate asthma, as well as healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.
"We are pleased to have completed the Phase 1 set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to asthmatic, as well as healthy human subjects, is an important step." commented Charles Scoggin, M.D., Chairman of N30 Pharma.
The primary endpoint of the study is patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201, including effects on the airway.
N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a critical store of nitric oxide (NO) bioactivity in the human airway.
About N30 Pharma
N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory and cardiovascular diseases. S-nitrosothiols are endogenous molecules which store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone. N30's drug development strategy focuses on administration of GSNO to the human airway, and the development of inhibitors of GSNO reductase. GSNO reductase is the key enzyme in the body that breaks down GSNO. These approaches allow N30 to deliver targeted, long lasting, physiologically relevant doses of s-nitrosothiols to target systems. N30 is a privately held company headquartered in Boulder, Colorado.
SOURCE N30 Pharma